Description: Nexien BioPharma, Inc., a pharmaceutical development company, engages in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals to address a range of medical conditions and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. The company is based in Glendale, Colorado. Nexien BioPharma, Inc. is a subsidiary of Intiva USA Inc.
Home Page: www.nexienbiopharma.com
4340 East Kentucky Avenue
Glendale,
CO
80246
United States
Phone:
303 495 7583
Officers
| Name | Title |
|---|---|
| Mr. Richard S. Greenberg | Founder, CEO, Exec. VP & Chairman |
| Mr. Evan L. Wasoff CPA | Chief Financial Officer |
| Mr. Robert I. Goldfarb J.D., Esq. | Chief Operating Officer |
| Dr. Linda Klumpers Ph.D. | Consultant |
| Mr. Joseph Morgan | Consultant |
| Mr. Paul Wilkenson Ph.D. | Consultant |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 205.4105 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |